Cholesterol drug increases pain-free walking distance

September 01, 2003

DALLAS, Sept 2 - A cholesterol-lowering drug has the added benefit of improving walking ability in people with peripheral artery disease which causes frequent leg pain, according to a report in today's rapid access issue of Circulation: Journal of the American Heart Association.

Peripheral artery disease is a condition caused by atherosclerosis, which also causes coronary artery disease and carotid artery disease. Fatty deposits build up in artery walls and restrict blood circulation, mainly in arteries leading to the legs and feet. A common symptom is intermittent claudication - cramping or fatigue in the legs and buttocks during activity that eases during rest.

About 5 percent of people age 60 and older are believed to have claudication, says Mark A. Creager, M.D., the study's senior author and director of the Vascular Center at Brigham and Women's Hospital, Boston.

Cholesterol-lowering drugs called statins have been shown to reduce heart attacks and other cardiovascular events in patients with atherosclerosis. Creager and colleagues investigated if the statin drug atorvastatin could also reduce claudication.

Researchers examined 354 people in their 60s with claudication in a randomized, double-blind study. Participants were treated daily with either a placebo, 10 milligrams (mg) of atorvastatin or 80 mg of atorvastatin for one year. Researchers measured the total amount of time that participants could walk on a treadmill, and how long they could walk without pain. Participants were also given a quality-of-life questionnaire to gauge their total energy expenditure at work and during home and leisure-time activities for the preceding week.

"The significance of the finding is that patients with claudication treated with a statin may experience an improvement in walking distance and lifestyle in addition to the known benefits of reduced risk for heart attack, stroke and death," Creager says.

As expected, researchers found that patients taking either dose of the cholesterol-lowering drug had reductions in their total cholesterol, LDL (bad) cholesterol and triglyercides, while their HDL (good) cholesterol increased. Cholesterol levels didn't improve in patients taking placebo.

Maximal walking time didn't differ significantly between the three groups. However, the amount of time participants could walk without having leg pain improved by 63 percent for patients taking 80 mg of atorvastatin. Pain-free walking time improved by about 38 percent for patients taking placebo and those taking 10 mg of atorvastatin.

On the quality-of-life questionnaire, people taking either dose of atorvastatin showed improvement in physical activity compared to people taking placebo, Creager says.

Creager notes that only 1.3 percent of patients receiving either dose of atorvastatin experienced a worsening of claudication, foot pain or underwent a procedure to open clogged arteries. The comparable figure for the placebo patients was 7.9 percent.

Researchers say there are several possible mechanisms at work. Statins may reduce the size of the fatty plaque deposits in the artery, improve blood flow or promote the formation of new blood vessels.

Co-authors are Emile R. Mohler III, M.D., and William R. Hiatt, M.D.
-end-
CONTACT: For journal copies only,
please call: 214-706-1396
For other information, call:
Carole Bullock: 214-706-1279
Bridgette McNeill: 214-706-1135
Julie Del Barto (broadcast): 214-706-1330

American Heart Association

Related Cholesterol Articles from Brightsurf:

Cholesterol's effects on cellular membranes
The findings have far-reaching implications in the general understanding of disease, the design of drug delivery methods, and many other biological applications that require specific assumptions about the role of cholesterol in cell membranes.

Autism-cholesterol link
Study identifies genetic link between cholesterol alterations and autism.

Microbes might manage your cholesterol
Researchers discover a link between human blood cholesterol levels and a gene in the microbiome that could one day help people manage their cholesterol through diet, probiotics, or entirely new types of treatment.

Experimental cholesterol-lowering drug effective at lowering bad cholesterol, study shows
Twice-yearly injections of an experimental cholesterol-lowering drug, inclisiran, were effective at reducing low-density lipoprotein (LDL) cholesterol, often called bad cholesterol, in patients already taking the maximum dose of statin drugs, according to data of the ORION-10 trial presented Saturday, Nov.

Rethinking how cholesterol is integrated into cells
Cholesterol is best known in connection with cardiovascular disease, but cholesterol is also vital for many fundamental processes in the body.

Seed oils are best for LDL cholesterol
Using a statistical technique called network meta-analysis, researchers have combined the results of dozens of studies of dietary oils to identify those with the best effect on patients' LDL cholesterol and other blood lipids.

Cholesterol leash: Key tethering protein found to transport cellular cholesterol
Cholesterol is an essential component of living organisms, but the mechanisms that transport cholesterol inside the cell are poorly understood.

New way to treat cholesterol may be on the horizon
A breakthrough discovery by scientists at Houston Methodist Research Institute could change the way we treat cholesterol.

How low should LDL cholesterol go?
New analysis shows that in a high-risk population, achieving ultra-low LDL cholesterol levels, down to <10 mg/dL, safely results in additional lowering of risk of cardiovascular events.

Does boosting 'good' cholesterol really improve your health?
A new review addresses the mysteries behind 'good' HDL cholesterol and why boosting its levels does not necessarily provide protection from cardiovascular risk for patients.

Read More: Cholesterol News and Cholesterol Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.